Covid-19 coronavirus – the UK’s preparation for a vaccine

Megan McMellon

The UK’s vaccine portfolio The UK Government has agreed supply deals for at least 340 million doses of six different vaccines, with most likely to require two doses: AstraZeneca and the University of Oxford (adenoviral vector vaccine, 100m doses); Johnson & Johnson (adenoviral vector vaccine, 30m doses, with an option to acquire an addition 22m Read More

French medical cannabis pilot: call for applications for suppliers launched today – responses required by 24 November


Today, the French National Agency for Medicines and Health Products Safety (ANSM) has officially launched the call for applications (“appel à candidatures”) for medical cannabis suppliers to participate in the pilot programme that will be started by 31 March at the latest.  The call for applications follows the publication of the ministerial order providing the Read More

Covid-19 coronavirus: patent database observations

Lars Braams

As per 8 September 2020, 143 search results containing the words “Covid 19” in the title, claims or the abstract of a patent show up in the international patent database Espacenet. Over the past weeks, this number grows with about 15 new results each week. While the race for a vaccine covers the headlines around Read More

EU: Derogation for Covid-19 clinical trials of medicinal products containing or consisting of genetically modified organisms

Veerle Pissierssens

In the context of the Covid-19 coronavirus pandemic, the European Union has adopted a Regulation providing for a temporary exemption from European legislation on genetically modified organisms (Regulation (EU) 2020/1043 of the European Parliament and of the Council of 15 July 2020 on the conduct of clinical trials with and supply of medicinal products for Read More

CJEU – The Grand Chamber reverses the Neurim decision

Charles Tuffreau

In a landmark decision dated 9 July 2020 concerning the Santen case (C‑673/18), the Grand Chamber of the CJEU clearly reverses the Neurim decision (C‑130/11) and ruled that a MA cannot be considered to be the first MA, for the purpose of Article 3(d), where it covers a new therapeutic application of an active ingredient Read More